Pca/active Surveillance

* Gaps in long-term data and areas for further research are identified, underscoring the need for careful application in clinical practice. This paper emphasises a multidisciplinary approach in patient selection, rigorous monitoring protocols, and fully informed decision-making. By presenting a...

* For clinicians considering TTh in men after prostate cancer treatment, several considerations should guide decision-making. Patient selection is critical with regular monitoring, with close attention to PSA velocity and testosterone levels. The benefits of treating hypogonadism, including...

“The 2018 AUA guidelines for testosterone therapy that were co-chaired by Dr. John P. Mulhall say that we have an absence or a paucity of data on using testosterone therapy on active surveillance,” says Helen L. Bernie, DO, MPH...

https://www.urotoday.com/conference-highlights/aua-2024/aua-2024-prostate-cancer/151946-aua-2024-crossfire-controversies-in-urology-testosterone-therapy-may-be-reasonably-offered-to-men-on-active-surveillance-pro-con.html (UroToday.com) Recent developments in urology have increasingly...